Evommune, Inc.
For the period ended Sep 30, 2025. Filed Dec 11, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Dec 11, 2025
EVMN$7.84+2.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations (unaudited)
(In thousands, except share and per share amounts)
| Three Months Ended · Nine Months Ended | ||||||||
|---|---|---|---|---|---|---|---|---|
| September 30, · September 30, | ||||||||
| 2025 · 2024 · 2025 · 2024 | ||||||||
| Revenues: | ||||||||
| License revenue | $ | 10,000 | $ | — | $ | 13,000 | $ | 7,000 |
| Operating expenses: | ||||||||
| Research and development | 19,639 | 13,289 | 53,639 | 46,413 | ||||
| General and administrative | 3,689 | 3,228 | 10,716 | 9,146 | ||||
| Total operating expenses | 23,328 | 16,517 | 64,355 | 55,559 | ||||
| Loss from operations | (13,328) | (16,517) | (51,355) | (48,559) | ||||
| Other income, net: | ||||||||
| Change in fair value of convertible preferred stock forward | — | — | 8,928 | — | ||||
| Interest income | 862 | 618 | 1,880 | 2,515 | ||||
| Other expense, net | (9) | (17) | (50) | (38) | ||||
| Total other income, net | 853 | 601 | 10,758 | 2,477 | ||||
| Net loss | (12,475) | (15,916) | (40,597) | (46,082) | ||||
| Net loss attributable to common stockholders | (12,475) | (15,916) | (40,597) | (46,082) | ||||
| Basic and diluted net loss per share of common stock | $ | (8.07) | $ | (10.47) | $ | (26.36) | $ | (30.69) |
| Weighted average basic and diluted shares of common stock outstanding | 1,545,010 | 1,520,814 | 1,540,243 | 1,501,635 | ||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.